Stryker (NYSE:SYK) Announces Quarterly Earnings Results

Key Points

• Stryker missed third-quarter expectations: Adjusted EPS was $3.52 versus the $3.55 consensus, while revenue totaled $6.52 billion compared with estimates of $6.62 billion.
• The company cut its 2026 outlook to 6.5%-7% organic sales growth and adjusted EPS of $14.80-$14.90, citing weakness in hip and knee procedures, supply constraints and cybersecurity and SAP-related disruptions.
• Profitability and cash generation remained resilient: Adjusted operating margin expanded to 26.2%, year-to-date operating cash flow rose about 14% to $3.3 billion, and Stryker authorized an additional $3 billion in share repurchases.

Stryker (NYSE:SYK - Get Free Report) announced its quarterly earnings results on Thursday. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts' consensus estimates of $3.55 by ($0.03), FiscalAI reports. The firm had revenue of $6.52 billion during the quarter, compared to analysts' expectations of $6.62 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%.

Here are the key takeaways from Stryker's conference call:

• Hip and knee weakness pressured results: Stryker said the large-joint market has slowed to roughly 2.5% growth, citing affordability concerns, insurance-related preauthorization denials and softer international conditions. The company also acknowledged that cyber and SAP implementation disruptions hurt commercial execution and new-product adoption.
• Stryker lowered its 2026 outlook to 6.5%-7% organic sales growth and adjusted EPS of $14.80-$14.90, reflecting weaker hip and knee trends, lingering peripheral vascular supply constraints and a more conservative view of capital-equipment execution.
• Margins and cash generation remained strong: Third-quarter adjusted EPS rose 10.3% to $3.52, adjusted operating margin expanded 60 basis points to 26.2%, and year-to-date operating cash flow increased about 14% to $3.3 billion. The board also authorized an additional $3 billion for share repurchases.
• MedSurg and Neurotechnology grew 9.1%, led by Endoscopy, Medical and Vascular, while capital demand and the order book remained elevated. Stryker expects strong fourth-quarter contributions from Trauma and Extremities, Medical and Instruments, and highlighted upcoming growth drivers including AVS, new power-tool and endoscopy platforms, Mako products and the CMR Surgical robotics partnership.

Stryker Price Performance

Shares of SYK traded up $7.12 during trading hours on Thursday, reaching $311.12. 3,059,300 shares of the company traded hands, compared to its average volume of 2,454,501. The stock has a market capitalization of $119.33 billion, a PE ratio of 32.24, a price-to-earnings-growth ratio of 1.98 and a beta of 0.78. The stock has a fifty day simple moving average of $294.14 and a 200 day simple moving average of $325.14. Stryker has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker's dividend payout ratio (DPR) is presently 36.48%.

Insider Activity at Stryker

In other Stryker news, insider Dylan Crotty sold 441 shares of the company's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda Stryker sold 300,000 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company's stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research reports. Barclays raised shares of Stryker to a "strong-buy" rating in a research note on Wednesday, October 7th. Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. Truist Financial reduced their price target on shares of Stryker from $340.00 to $310.00 and set a "hold" rating on the stock in a report on Tuesday, October 6th. Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Saturday, October 3rd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $369.00.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter sales increased 7.7%, reflecting continued demand for Stryker’s medical equipment and products. Management also highlighted recovery progress following the cybersecurity incident disclosed earlier in 2026. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management expects 2026 organic net sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90. Stryker’s latest analyst price targets remain above the current trading level, but those targets may be revised after the outlook reduction. Stryker Q3 2026 Earnings Call Transcript
• Negative Sentiment: Adjusted third-quarter EPS was $3.52, below the $3.55 consensus estimate, while revenue of $6.52 billion missed expectations of $6.62 billion. Quarterly profit declined year over year, indicating that revenue growth was not sufficient to offset margin and operating pressures. Stryker Lowers Outlook After 3Q Profit Falls
• Negative Sentiment: The company lowered its prior 2026 forecasts from 8.3%–9.3% organic sales growth and $14.95–$15.10 adjusted EPS. Investors are also monitoring manufacturing constraints affecting the vascular business, along with lingering effects from the cybersecurity incident. Stryker Slides After Lowering 2026 Outlook
• Negative Sentiment: Recent insider activity shows reported sales without purchases over the past six months, including substantial selling by director Ronda E. Stryker. While insider transactions may be unrelated to near-term fundamentals, the pattern can add to investor caution.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.